For example, both tocilizumab and sarilumab could alleviate the inflammatory factor IL-6 in patients with rheumatoid arthritis, and therefore reverse the increased IL-6–mediated suppression of CYP3A4 and further reduce the elevated systemic exposures of simvastatin and simvastatin acid in such disease status (Schmitt et al., 2011; Lee et al., 2017). This evidence concerns the gene IL6 and rheumatoid arthritis.